CollPlant Biotechnologies (CLGN) Non-Current Assets (2017 - 2025)
CollPlant Biotechnologies (CLGN) posted Non-Current Assets of $4.0 million for Q4 2025, down 16.1% on a QoQ basis from $4.8 million in Q2 2025, and down 99.93% year-over-year from $5.5 billion in Q4 2024.
CollPlant Biotechnologies (CLGN) Non-Current Assets (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies' Non-Current Assets history runs 9 years deep, the most recent figure standing at $4.0 million for Q4 2025.
- Quarterly Non-Current Assets fell 99.93% year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.0 million (down 99.93% YoY) and the FY2025 annual result came in at $4.0 million, down 99.93% from the prior year.
- Non-Current Assets was $4.0 million for Q4 2025 at CollPlant Biotechnologies, down from $4.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $6137.0 billion in Q4 2021 and bottomed at $4.0 million in Q4 2025.
- A 5-year average of $342.9 billion and a median of $6.5 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets surged 118818873.86% — and 2025, when it plunged 99.93%.
- CollPlant Biotechnologies' Non-Current Assets stood at $6137.0 billion in 2021, then sank by 99.9% to $6.1 billion in 2022, then plunged by 99.9% to $6.1 million in 2023, then jumped by 90496.33% to $5.5 billion in 2024, then plunged by 99.93% to $4.0 million in 2025.
- Business Quant data shows CLGN's Non-Current Assets at $4.0 million in Q4 2025, $4.8 million in Q2 2025, and $5.5 billion in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,913.26 Bn | 1,913.20 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.02 Bn | 466.23 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 122.17 Bn | 114.92 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.10 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.60 Bn | 50.42 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Alnylam Pharmaceuticals | 37.39 Bn | 34.38 Bn | 959.66 Mn | 910.24 Mn |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.04 Mn |
| Jun 30, 2025 | 4.81 Mn |
| Dec 31, 2024 | 5.53 Bn |
| Sep 30, 2024 | 5.95 Bn |
| Jun 30, 2024 | 6.23 Mn |
| Mar 31, 2024 | 5.82 Bn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 6.35 Bn |
| Jun 30, 2023 | 6.71 Mn |
| Mar 31, 2023 | 6.70 Mn |
| Dec 31, 2022 | 6.11 Bn |
| Sep 30, 2022 | 6.10 Mn |
| Jun 30, 2022 | 6.14 Mn |
| Mar 31, 2022 | 6.11 Mn |
| Dec 31, 2021 | 6,137.00 Bn |
| Sep 30, 2021 | 5.73 Mn |
| Jun 30, 2021 | 5.25 Mn |
| Mar 31, 2021 | 5.17 Bn |
| Dec 31, 2020 | 5.17 Mn |
| Sep 30, 2020 | 5.32 Mn |